Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
66
PROF Quote, Financials, Valuation and Earnings
Last price:
$7.89
Seasonality move
:
31.45%
Day range:
$7.10 - $7.39
52-week range:
$3.76 - $7.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.86x
P/B ratio:
6.89x
Volume:
62.3K
Avg. volume:
87K
1-year change:
-1.35%
Market cap:
$221.3M
Revenue:
$10.7M
EPS (TTM):
-$1.34
Analysts' Opinion
-
Consensus RatingProfound Medical Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.10, Profound Medical Corp. has an estimated upside of 65.08% from its current price of $7.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $7.33.
Fair Value
-
According to the consensus of 4 analysts, Profound Medical Corp. has 65.08% upside to fair value with a price target of $12.10 per share.
PROF vs. S&P 500
-
Over the past 5 trading days, Profound Medical Corp. has overperformed the S&P 500 by 11.76% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Profound Medical Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Profound Medical Corp. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Profound Medical Corp. reported revenues of $5.3M.
Earnings Growth
-
Profound Medical Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Profound Medical Corp. reported earnings per share of -$0.27.
Enterprise value:
201.3M
EV / Invested capital:
5.45x
Price / LTM sales:
14.86x
EV / EBIT:
--
EV / Revenue:
14.08x
PEG ratio (5yr expected):
-0.24x
EV / Free cash flow:
-5.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$10.4M
Return On Assets:
-61.68%
Net Income Margin (TTM):
-275.16%
Return On Equity:
-92.06%
Return On Invested Capital:
-82.14%
Operating Margin:
-168.52%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $6.4M | $9M | $14.3M | $2.8M | $5.3M | |
| Gross Profit | $3.8M | $5.6M | $10.4M | $1.8M | $3.9M | |
| Operating Income | -$26.2M | -$33.1M | -$42.2M | -$9M | -$8.9M | |
| EBITDA | -$25.3M | -$32M | -$41.6M | -$8.7M | -$8.8M | |
| Diluted EPS | -$1.38 | -$1.34 | -$1.34 | -$0.38 | -$0.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $87.3M | $57.6M | $48.3M | $40.9M | $41.5M | |
| Total Assets | $93.6M | $64.1M | $50.4M | $42.2M | $42.3M | |
| Current Liabilities | $3.6M | $3.3M | $5.2M | $6.7M | $9.9M | |
| Total Liabilities | $5.6M | $5M | $11.9M | $11.2M | $10.2M | |
| Total Equity | $88M | $60.1M | $38.6M | $31.1M | $32.1M | |
| Total Debt | $1.5M | $1.1M | $8.1M | $5.9M | $4.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$21.8M | -$25M | -$37.6M | -$6.3M | -$9.7M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $8.9M | $18.8M | $34.1M | -$661.4K | $900 | |
| Free Cash Flow | -$21.8M | -$25M | -$37.6M | -$6.3M | -$9.7M | |
PROF
Sector
Market Cap
$221.3M
$29M
Price % of 52-Week High
91.74%
52.89%
Dividend Yield
0%
0%
Shareholder Yield
-25.51%
-1.4%
1-Year Price Total Return
-1.35%
-19%
Beta (5-Year)
0.569
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.03
200-day SMA
Buy
Level
$5.62
Bollinger Bands (100)
Buy
Level
4.66 - 6.42
Chaikin Money Flow
Sell
Level
-751.7K
20-day SMA
Buy
Level
$6.60
Relative Strength Index (RSI14)
Buy
Level
65.14
ADX Line
Buy
Level
27.35
Williams %R
Sell
Level
-11.6279
50-day SMA
Buy
Level
$6.21
MACD (12, 26)
Buy
Level
0.33
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
2.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.8263)
Sell
CA Score
(Annual)
Level (-2.1484)
Buy
Beneish M-Score
(Annual)
Level (-2.5287)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.273)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm’s product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It is also focused on developing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company was founded on June 13, 2008 and is headquartered in Mississauga, Canada.
Stock Forecast FAQ
In the current month, PROF has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PROF average analyst price target in the past 3 months is $12.10.
-
Where Will Profound Medical Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Profound Medical Corp. share price will rise to $12.10 per share over the next 12 months.
-
What Do Analysts Say About Profound Medical Corp.?
Analysts are divided on their view about Profound Medical Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Profound Medical Corp. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Profound Medical Corp.'s Price Target?
The price target for Profound Medical Corp. over the next 1-year time period is forecast to be $12.10 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PROF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Profound Medical Corp. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PROF?
You can purchase shares of Profound Medical Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Profound Medical Corp. shares.
-
What Is The Profound Medical Corp. Share Price Today?
Profound Medical Corp. was last trading at $7.89 per share. This represents the most recent stock quote for Profound Medical Corp.. Yesterday, Profound Medical Corp. closed at $7.33 per share.
-
How To Buy Profound Medical Corp. Stock Online?
In order to purchase Profound Medical Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PROF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PROF
Sector
P/E ratio
--
24.19x
PEG ratio
-0.24x
-0.01x
P/B ratio
6.89x
1.84x
Price / LTM sales
14.86x
1.61x
Growth Metrics
PROF
Sector
Revenue growth
86.76%
4.6%
Earnings growth
30.57%
10.88%
Revenue (5-year growth)
20.72%
6.5%
Earnings forecast
-$0.38
-$0.20
Profitability
PROF
Sector
Profitability FY 2024
$7M
$3.5M
Return on invested capital
-82.14%
-31.66%
Return on assets
-61.68%
-27.84%
Return on equity
-92.06%
-37.15%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
12
Balance Sheet
PROF
Sector
Total cash
$24.8M
$26.8M
Short term investments
--
$26M
Total assets
$123.8M
$79.7M
Long term debt
$4.5M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 4.13% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 2.57% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 4.39% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
